^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC).

Published date:
02/13/2023
Excerpt:
...we report the results from stage 1 of a phase II neoadjuvant trial of N+I for cisplatin-ineligible patients (pts) with UTUC….Three pts had confirmed pathogenic germline variants in mismatch repair genes (MSH2, n=2; MLH1, n=1), all of which achieved pCR (n=1) or ypTaN0 (n=2) and remained alive and disease-free at last follow-up.
DOI:
10.1200/JCO.2023.41.6_suppl.511
Trial ID: